BioLineRx (BLRX) Other financing activities (2013 - 2024)

BioLineRx's Other financing activities history runs 13 years deep, the most recent figure standing at $725000.0 for Q3 2025.

• In Q3 2025, Other financing activities rose 192.12% year-over-year to $725000.0; the TTM figure through Sep 2025 stood at -$900000.0 (down 109.75% YoY), while the FY2024 annual figure was $22000.0, down 99.25% from the prior year.
• Other financing activities for Q3 2025 stood at $725000.0, up from -$1.8 million in the prior quarter.
• The five-year high for Other financing activities was $16.0 million in Q1 2021, with the low at -$13.1 million in Q4 2022.
• The 5-year median for Other financing activities is $725000.0 (2025), against an average of $1.3 million.
• Peak annual rise in Other financing activities reached 250.0% in 2024, while the deepest fall reached 2314.57% in 2024.
• BioLineRx's Other financing activities stood at -$5.1 million in 2021, then tumbled by 154.86% to -$13.1 million in 2022, then soared by 103.04% to $398000.0 in 2023, then sank by 2314.57% to -$8.8 million in 2024, then surged by 108.23% to $725000.0 in 2025.
• Business Quant data shows BLRX's Other financing activities at $725000.0 in Q3 2025, -$1.8 million in Q2 2025, and $9.0 million in Q1 2025.